← Leaderboards
Thomas F Deuel
Beth Israel Deaconess Medical Center
$8,069,433
Attributed
$8,069,433
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$8,069,433 · 6
By mechanism
R01$7,682,646 · 5
P50$386,787 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Harold Fisher Dvorak$13,877,917
- S. Nahum Goldberg$4,968,299
- Elliot Chaikof$40,570,541
- Robert C Flaumenhaft$19,499,862
- Bruce Furie$39,376,853
Others in their field
Top investigators on “Athymic Mouse”
- Ralph Weissleder · Massachusetts General Hospital$5,688,124
- Donald P McDonnell · Duke University$5,386,390
- Oliver W. Press · Fred Hutchinson Cancer Research Center$5,178,285
- Channing J Der · University Of North Carolina Chapel Hill$4,926,790
- Murray Korc · University Of California Irvine$4,764,672
- John Blenis · Harvard University (Medical School)$4,611,687
Research focus
Athymic MouseBiological Signal TransductionGene ExpressionNeoplastic TransformationProtein Structure FunctionTissue /Cell CultureAngiogenesisCell Growth RegulationWestern BlottingsOncogenesNerve Growth FactorsBreast NeoplasmsNeoplasm /Cancer GeneticsEnzyme ActivityNorthern BlottingsGenetically Modified AnimalsPlatelet Derived Growth FactorAngiogenesis FactorDisease /Disorder ModelCytokineMitogensCardiovascular NeoplasmIsozymesNeoplastic Cell
Grant awards (21)
ROLE OF PLEIOTROPHIN IN BREAST CANCER$530,372
R01 · FY2004 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$487,337
R01 · FY2004 · CA
OXIDASE RELATED 48K PHOSPHOPROTEIN OF HUMAN NEUTROPHILS$398,925
R01 · FY2004 · AI
ROLE OF PLEIOTROPHIN IN BREAST CANCER$515,086
R01 · FY2003 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$476,960
R01 · FY2003 · CA
PLATELET AND CELL GROWTH--ROLE OF PDGF$592,625
R01 · FY2002 · HL
ROLE OF PLEIOTROPHIN IN BREAST CANCER$500,084
R01 · FY2002 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$412,583
R01 · FY2002 · CA
PLEIOTROPHIN SIGNALING MECHANISMS$356,660
R01 · FY2002 · DK
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$58,097
R01 · FY2002 · CA
PLATELET AND CELL GROWTH--ROLE OF PDGF$523,878
R01 · FY2001 · HL
ROLE OF PLEIOTROPHIN IN BREAST CANCER$456,157
R01 · FY2001 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$376,077
R01 · FY2001 · CA
PLEIOTROPHIN SIGNALING MECHANISMS$326,003
R01 · FY2001 · DK
PDGF IN DEVELOMENT AND SIGNALING$274,326
P50 · FY2001 · HL
PLATELET AND CELL GROWTH--ROLE OF PDGF$18,640
R01 · FY2001 · HL
PLATELET AND CELL GROWTH--ROLE OF PDGF$528,664
R01 · FY2000 · HL
ROLE OF PLEIOTROPHIN IN BREAST CANCER$442,870
R01 · FY2000 · CA
PLEIOTROPHIN-- AN ANGIOGENIC SWITCH IN TUMOR PROGRESSION$365,122
R01 · FY2000 · CA
PLEIOTROPHIN SIGNALING MECHANISMS$316,506
R01 · FY2000 · DK
PDGF IN DEVELOMENT AND SIGNALING$112,461
P50 · FY2000 · HL